TScan Therapeutics Stock Forecast

TCRX's stock price has decreased by -82.59% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 6 analysts polled by S&P Global, TScan Therapeutics stock has a consensus rating of "Hold" and an average price target of $2.67. The average 1-year stock price forecast is 733.33% higher than the current stock price, while the lowest is $1.00 (+212.11%) and the highest is $6.00 (+1,772.66%).

Price Target: $2.67 (+733.33%)

Analyst Consensus: Hold

Price Target

Chart

Target	Low	Average	Median	High
Price	$1.00	$2.67	$1.00	$6.00
Change	+212.11%	+733.33%	+212.11%	+1772.7%

Analyst Ratings

The average analyst rating for TScan Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	4	4	4	4	4	2
Buy	1	1	1	1	1	0
Hold	1	1	1	1	1	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Hold Downgrades $7 → $1	Hold	Downgrades	$7 → $1	+212.11%	Sep 8, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Sep 2, 2026
Gil Blum Needham	Needham	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Sep 2, 2026
David Nierengarten Wedbush	Wedbush	Hold Downgrades $5 → $1	Hold	Downgrades	$5 → $1	+212.11%	Sep 2, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Aug 17, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

4.51M

from 10.33M

-56.37%

from 10.33M

Revenue Next Year

3.28M

from 4.51M

-27.27%

from 4.51M

EPS This Year

-0.78

from -1.00

EPS Next Year

-0.57

from -0.78

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	10.14M	13.54M	21.05M	2.82M	10.33M	4.51M
Revenue Growth	834.65%	33.47%	55.52%	-86.62%	266.66%	-56.37%
Operating Income	-48.64M	-66.64M	-93.46M	-134.82M	-133.81M	-106.50M
Net Income	-48.63M	-66.22M	-89.22M	-127.50M	-129.77M	-104.86M
EPS	-	-	-	-	-1.00	-0.78
Free Cash Flow	-33.43M	-42.84M	-41.83M	-68.97M	-97.25M	-56.33M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	10.8M
Avg	4.5M
Low	2.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	5.0%
Avg	-56.4%
Low	-80.3%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.62
Avg	-0.78
Low	-0.89

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-